Previous 10 | Next 10 |
KAZIA THERAPEUTICS APPOINTS KAREN KRUMEICH AS CHIEF FINANCIAL OFFICER PR Newswire SYDNEY , Dec. 13, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the appointment of ...
Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma PR Newswire SYDNEY , Dec. 4, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company,...
Additional phase 2 data for Kazia Therapeutics' (NASDAQ:KZIA) paxalisib for glioblastoma found the drug led to an average overall survival of 15.7 months compared to a control on patients who took temozolomide. Average progression-free survival was 8.4 months with paxalisib compared to 5.3 mo...
GBM AGILE Opens to Paxalisib in Canada Canada NewsWire SYDNEY , Nov. 29, 2021 /CNW/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to inform stakeholders that the GBM AGILE study in glioblasto...
Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer PR Newswire SYDNEY , Nov. 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the appointment of ...
Medicenna Therapeutics has engineered super-versions of interleukins, proteins that mediate communication between cells. Medicenna’s candidate for treating rGBM, MDNA55, has shown promising efficacy and safety data in its recently concluded phase II trial. MDNA11, an IL-2 s...
Kazia Therapeutics (NASDAQ:KZIA) has commenced enrollment to a phase I clinical trial of EVT801, an investigational cancer therapy that Kazia licensed from Evotec SE in April 2021. The phase I study will focus primarily on understanding the safety, tolerability, and pharmacokinetics of E...
PNOC Study in Childhood Brain Cancer Enrols First Patient PR Newswire SYDNEY , Nov. 11, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that PNOC022 (NCT05009992), a mu...
Kazia Enrols First Patient to EVT801 Phase I Clinical Trial PR Newswire SYDNEY , Nov. 4 , 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has commenced enr...
LONDON, UK / ACCESSWIRE / October 14, 2021 / Kazia expects to release multiple data points from its paxalisib program in Q4 CY21. These include final data from the 30-patient Phase II trial in newly diagnosed glioblastoma multiforme (GBM) patients, as well as initial data for paxalisib in th...
News, Short Squeeze, Breakout and More Instantly...
Kazia Therapeutics Limited Company Name:
KZIA Stock Symbol:
NASDAQ Market:
Kazia Therapeutics Limited Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 0.6% to $128.44 on volume of 203,267,889 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 22.1% to $0.5152 on volume of 200,531,827 shares PROSHARES TRUST (SQQQ) fell 0.7% to $7.46 on volume o...
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...